JP2018525001A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525001A5
JP2018525001A5 JP2018506183A JP2018506183A JP2018525001A5 JP 2018525001 A5 JP2018525001 A5 JP 2018525001A5 JP 2018506183 A JP2018506183 A JP 2018506183A JP 2018506183 A JP2018506183 A JP 2018506183A JP 2018525001 A5 JP2018525001 A5 JP 2018525001A5
Authority
JP
Japan
Prior art keywords
cell
nucleic acid
permeable conjugate
cell permeable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525001A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/045819 external-priority patent/WO2017024239A1/en
Publication of JP2018525001A publication Critical patent/JP2018525001A/ja
Publication of JP2018525001A5 publication Critical patent/JP2018525001A5/ja
Pending legal-status Critical Current

Links

JP2018506183A 2015-08-06 2016-08-05 治療用細胞内在化コンジュゲート Pending JP2018525001A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201993P 2015-08-06 2015-08-06
US62/201,993 2015-08-06
PCT/US2016/045819 WO2017024239A1 (en) 2015-08-06 2016-08-05 Therapeutic cell internalizing conjugates

Publications (2)

Publication Number Publication Date
JP2018525001A JP2018525001A (ja) 2018-09-06
JP2018525001A5 true JP2018525001A5 (https=) 2019-09-12

Family

ID=57943993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506183A Pending JP2018525001A (ja) 2015-08-06 2016-08-05 治療用細胞内在化コンジュゲート

Country Status (7)

Country Link
US (1) US20180243436A1 (https=)
EP (1) EP3331573A4 (https=)
JP (1) JP2018525001A (https=)
CN (1) CN108136042A (https=)
AR (1) AR105641A1 (https=)
TW (1) TW201718024A (https=)
WO (1) WO2017024239A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36519A (es) 2015-01-16 2016-08-31 Hope City Anticuerpos de penetración celular
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
JP7406793B2 (ja) * 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ 2テイル自己デリバリー型siRNAおよび関連方法
WO2019014650A1 (en) * 2017-07-13 2019-01-17 City Of Hope ANTICANCER CONJUGATES OF PEPTIDE COUPLED WITH PHOSPHOROTHIOATE AND METHODS OF USE THEREOF
JP7295838B2 (ja) * 2017-07-13 2023-06-21 シティ・オブ・ホープ ホスホロチオエートコンジュゲートペプチド及びその使用方法
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
CA3147366A1 (en) * 2019-08-14 2021-02-18 Adam T. BOUTIN Extracellular vesicles with stat3-antisense oligonucleotides
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
WO2021242883A1 (en) 2020-05-26 2021-12-02 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
CN117677699A (zh) 2021-06-23 2024-03-08 马萨诸塞大学 用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
EP4634373A1 (en) 2022-12-16 2025-10-22 University of Rochester Repairment of barrier dysfunction in esophagus
WO2024151843A1 (en) * 2023-01-11 2024-07-18 The Johns Hopkins University Targeted universal delivery system of don and other drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1912677T3 (da) * 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
WO2009012359A2 (en) * 2007-07-17 2009-01-22 The General Hospital Corporation Matrix metalloprotease targeting nucleic acids
DK2644194T3 (en) * 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US20110218334A1 (en) * 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
EP2681557A4 (en) * 2011-03-04 2015-07-08 Bio Rad Laboratories SIGNAL REINFORCEMENT FOR IMMUNOASSAYS THROUGH AVIDIN BIOTIN BINDINGS
US10793913B2 (en) * 2013-03-08 2020-10-06 City Of Hope Methods and compositions for treatment of breast cancer
CN105658230B (zh) * 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
WO2015070080A2 (en) * 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Nucleic acid nanostructures for in vivo agent delivery

Similar Documents

Publication Publication Date Title
JP2018525001A5 (https=)
Zheng et al. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping
Dassie et al. Current progress on aptamer-targeted oligonucleotide therapeutics
Kim et al. Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
Arnold et al. Antibody-antisense oligonucleotide conjugate downregulates a key gene in glioblastoma stem cells
Fang et al. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach
Chen et al. Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology
Kruspe et al. Aptamer-siRNA chimeras: discovery, progress, and future prospects
Zhou et al. Aptamers: A promising chemical antibody for cancer therapy
Ray et al. Aptamers for targeted drug delivery
Mahlknecht et al. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
Guo et al. Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application
Wang et al. Automated modular synthesis of aptamer–drug conjugates for targeted drug delivery
Yoon et al. Targeted delivery of C/EBPα-saRNA by pancreatic ductal adenocarcinoma-specific RNA aptamers inhibits tumor growth in vivo
Kanwar et al. Chimeric aptamers in cancer cell-targeted drug delivery
Cerchia et al. Targeting cancer cells with nucleic acid aptamers
Kruspe et al. Aptamers as drug delivery vehicles
Perche et al. Hydroxychloroquine-conjugated gold nanoparticles for improved siRNA activity
Xu et al. Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression
JP2018525381A5 (https=)
JP2010523487A5 (https=)
Meyer et al. Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells
Cesarini et al. The recent blooming of therapeutic aptamers
JP2021167329A5 (https=)
Li et al. Nanoparticle-conjugated aptamer targeting hnRNP A2/B1 can recognize multiple tumor cells and inhibit their proliferation